IAVI V001

Status:Completed

Phase:I

Principal Investigator(s):

Objective:Trial to test the safety and immunogenicity of a multi-clade HIV-1 DNA plasmid followed by recombinant multiclade HIV-1 adenoviral vector vaccine or the multi-clade HIV-1 adenoviral vector alone.

Prevention Option(s):HIV Vaccine

Study Design:

Arms and Assigned Interventions

DescriptionMulti-clade HIV-1 DNA plasmid followed by recombinant multiclade HIV-1 adenoviral vector vaccine or the multi-clade HIV-1 adenoviral vector alone

Mode of Delivery

ARMsExperimental

Official Code: IAVI V001

Trial Sponsors: Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Kenya; Projet San Francisco (PSF-Kigali)

Start Date

End Date

none

Enrollment:114

Age range: ↔ any

Population:

Stay up-to-date!